Genomics

Ikarovec

In August 2018 Ikarovek was formed to commercialise certain orphan assets from Quethera, a spin-out from the University of Cambridge, which was acquired by Astellas Pharma Inc.

Initially Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.

OxSyBio

OxSyBio is developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical applications.

The technology is based on cutting-edge research conducted by Professor Hagan Bayley’s group in the Chemistry Department at the University of Oxford. A leader in the exploration of membrane protein structure and function, Professor Bayley’s group developed […]

Predictimmune

, ,

We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes.

Their first offering, PredictImmune-CD, will be […]

Congenica

, ,

We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department of Health. Congenica has developed software that enables the accurate, rapid and scalable clinical interpretation of genetic and clinical data.

Congenica’s technology is […]

Quethera

,

In August 2018 Quethera, a spin-out from the University of Cambridge, was acquired by Astellas Pharma Inc. Under the terms of the purchase agreement, Astellas may pay up to £85 million in aggregate consideration (upfront and contingent payments) to Quethera shareholders as described here.

Quethera is a gene therapy company developing a novel treatment for glaucoma, developing methods […]

PhoreMost

, , ,

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

PhoreMost believes it is uniquely placed […]

Horizon Discovery

,

Horizon's basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.

DefiniGEN

, , ,

DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes.